Research Analysts Offer Predictions for HBIO Q3 Earnings

Harvard Bioscience, Inc. (NASDAQ:HBIO – Free Report) – Stock analysts at Sidoti issued their Q3 2026 EPS estimates for shares of Harvard Bioscience in a note issued to investors on Saturday, October 31st. Sidoti analyst J. Sidoti expects that the medical instruments supplier will earn ($0.65) per share for the quarter. The consensus estimate for Harvard Bioscience’s current full-year earnings is ($2.44) per share. Sidoti also issued estimates for Harvard Bioscience’s Q4 2026 earnings at ($0.39) EPS, FY2026 earnings at ($2.44) EPS, Q1 2027 earnings at ($0.37) EPS, Q2 2027 earnings at ($0.34) EPS, Q3 2027 earnings at ($0.36) EPS, Q4 2027 earnings at ($0.09) EPS, FY2027 earnings at ($1.15) EPS, Q1 2028 earnings at $0.06 EPS, Q2 2028 earnings at $0.06 EPS, Q3 2028 earnings at $0.05 EPS and FY2028 earnings at $0.43 EPS.

Other research analysts also recently issued reports about the company. Zacks Research initiated coverage on Harvard Bioscience in a research note on Tuesday. They set a “hold” rating for the company. Benchmark boosted their price objective on Harvard Bioscience from $6.00 to $7.50 and gave the stock a “speculative buy” rating in a report on Wednesday, August 12th. Finally, Weiss Ratings cut Harvard Bioscience from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 14th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $6.75.

Get Our Latest Analysis on Harvard Bioscience

Harvard Bioscience Stock Down 1.7%

HBIO stock opened at $8.46 on Wednesday. The company has a debt-to-equity ratio of 4.94, a quick ratio of 0.98 and a current ratio of 1.87. The business has a 50 day moving average price of $8.20 and a two-hundred day moving average price of $6.49. Harvard Bioscience has a twelve month low of $4.00 and a twelve month high of $9.10.

Harvard Bioscience (NASDAQ:HBIO – Get Free Report) last released its earnings results on Tuesday, August 11th. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.07. Harvard Bioscience had a negative return on equity of 33.13% and a negative net margin of 11.86%. The business had revenue of $22.73 million for the quarter, compared to the consensus estimate of $21.45 million.

Institutional Investors Weigh In On Harvard Bioscience

An institutional investor recently bought a new stake in Harvard Bioscience stock. Citadel Advisors LLC purchased a new stake in Harvard Bioscience, Inc. (NASDAQ:HBIO – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 13,251 shares of the medical instruments supplier’s stock, valued at approximately $81,000. Citadel Advisors LLC owned approximately 0.29% of Harvard Bioscience as of its most recent filing with the Securities & Exchange Commission. 80.87% of the stock is currently owned by hedge funds and other institutional investors.

Harvard Bioscience News Summary

Here are the key news stories impacting Harvard Bioscience this week:

  • Positive Sentiment: Sidoti’s forecasts point to a potential recovery, with estimated earnings of $0.43 per share for FY2028 after projected losses in FY2026 and FY2027. Sidoti estimates
  • Neutral Sentiment: Zacks Research initiated coverage with a “hold” rating, indicating a wait-and-see stance rather than a clear bullish or bearish view. Zacks Research ratings
  • Neutral Sentiment: CEO John Duke and CFO Mark Frost are scheduled to participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum on November 11; the appearance may offer investor visibility but is not itself a financial update. Forum announcement
  • Negative Sentiment: Margin concerns remain a risk ahead of Q3 results. Sidoti estimates losses of $2.44 per share for FY2026 and $1.15 for FY2027, reinforcing near-term earnings pressure despite its projected 2028 improvement. Q3 and margin concerns

Harvard Bioscience Company Profile

(Get Free Report)

Harvard Bioscience, Inc (NASDAQ: HBIO) develops, manufactures and supplies specialized tools, equipment and consumables used in biomedical research, drug discovery and related life science applications. Its products support work in areas such as cell biology, electrophysiology, gene delivery, organ-on-chip research and preclinical studies.

The company’s portfolio includes laboratory instruments, tissue and organ perfusion systems, electrophysiology equipment, cell and molecular biology products, and related consumables.

Recommended Stories

Earnings History and Estimates for Harvard Bioscience (NASDAQ:HBIO)

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.